Search

Your search keyword '"Uleer, C."' showing total 152 results
Start Over Author "Uleer, C."
152 results on '"Uleer, C."'

1. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Author

Martín, M., Stecklein, S.R., Gluz, O., Villacampa, G., Monte-Millán, M., Nitz, U., Cobo, S., Christgen, M., Brasó-Maristany, F., Álvarez, E.L., Echavarría, I., Conte, B., Kuemmel, S., Bueno-Muiño, C., Jerez, Y., Kates, R., Cebollero, M., Kolberg-Liedtke, C., Bueno, O., García-Saenz, J.Á., Moreno, F., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Wuerstleins, R., Graeser, M., zu Eulenburg, C., Kreipe, H.H., Gómez, H., Massarrah, T., Herrero, B., Paré, L., Bohn, U., López-Tarruella, S., Vivancos, A., Sanfeliu, E., Parker, J.S., Perou, C.M., Villagrasa, P., Prat, A., Sharma, P., and Harbeck, N.

Published
2024
Full Text
View/download PDF

2. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Author

Gluz, O., Kuemmel, S., Nitz, U., Braun, M., Lüdtke-Heckenkamp, K., von Schumann, R., Darsow, M., Forstbauer, H., Potenberg, J., Uleer, C., Grischke, E.M., Aktas, B., Schumacher, C., zu Eulenburg, C., Kates, R., Jóźwiak, K., Graeser, M., Wuerstlein, R., Baehner, R., Christgen, M., Kreipe, H.H., and Harbeck, N.

Published
2023
Full Text
View/download PDF

3. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Author

Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., and Loibl, S.

Published
2021
Full Text
View/download PDF

5. 18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)

Author

Graeser, M., primary, Harbeck, N., additional, Gluz, O., additional, Nitz, U.A., additional, Christgen, M., additional, Kuemmel, S., additional, Grischke, E-M., additional, Forstbauer, H., additional, Braun, M., additional, Warm, M., additional, Hackmann, J.C., additional, Uleer, C., additional, Aktas, B., additional, Würstlein, R., additional, Pelz, E., additional, Eulenburg, C. Zu, additional, Kreipe, H., additional, Trau, M., additional, Stirzaker, C., additional, and Korbie, D., additional

Published
2023
Full Text
View/download PDF

6. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Author

von Minckwitz, G., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P.A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Huober, J., Solbach, C., Jackisch, C., Kunz, G., Blohmer, J.U., Hauschild, M., Fehm, T., Nekljudova, V., Gerber, B., Gnauert, K., Heinrich, B., Prätz, T., Groh, U., Tanzer, H., Villena, C., Tulusan, A., Liedtke, B., Blohmer, J.-U., Mau, C., Potenberg, J., Schilling, J., Just, M., Weiss, E., Bückner, U., Wolfgarten, M., Lorenz, R., Doering, G., Feidicker, S., Krabisch, P., Deichert, U., Augustin, D., Kast, K., Nestle-Krämling, C., Höß, C., Terhaag, J., Fasching, P., Staib, P., Aktas, B., Kühn, T., Khandan, F., Möbus, V., Stickeler, E., Heinrich, G., Wagner, H., Abdallah, A., Dewitz, T., Emons, G., Belau, A., Rethwisch, V., Lantzsch, T., Thomssen, C., Mattner, U., Nugent, A., Müller, V., Noesselt, T., Holms, F., Müller, T., Deuker, J.-U., Strumberg, D., Uleer, C., Solomayer, E., Runnebaum, I., Link, H., Tomé, O., Ulmer, H.-U., Conrad, B., Feisel-Schwickardi, G., Schumacher, C., Steinmetz, T., Bauerfeind, I., Kremers, S., Langanke, D., Kullmer, U., Ober, A., Fischer, D., Kohls, A., Weikel, W., Bischoff, J., Freese, K., Schmidt, M., Wiest, W., Sütterlin, M., Dietrich, M., Grießhammer, M., Burgmann, D.-M., Rack, B., Salat, C., Sattler, D., Tio, J., von Abel, E., Christensen, B., Burkamp, U., Köhne, C.-H., Meinerz, W., Graßhoff, S.-T., Decker, T., Overkamp, F., Thalmann, I., Sallmann, A., Beck, T., Reimer, T., Bartzke, G., Deryal, M., Weigel, M., Weder, P., Steffens, C.-C., Lemster, S., Stefek, A., Ruhland, F., Hofmann, M., Schuster, J., Simon, W., Kronawitter, U., Clemens, M., Janni, W., Latos, K., Bauer, W., Roßmann, A., Bauer, L., Lampe, D., Heyl, V., Hoffmann, G., Lorenz-Salehi, F., Hackmann, J., and Schlag, R.

Published
2014
Full Text
View/download PDF

9. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Author

Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U, Loibl, S., Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U, and Loibl, S.

Abstract

Background: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTriais gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD. Patients and methods: Patients with untreated primary HER2-negative cT2-cT4a-d or cT1c with either cN + or pNSIN + or cT1c and triple-negative breast cancer (TNBC) or cT1c and Ki-67>20% BC with HRD were randomised either to paclitaxel (P) 80 mg/m(2) weekly plus olaparib (0) 100 mg twice daily for 12 weeks or P plus carboplatinum (Cb) area under the curve 2 weekly for 12 weeks, both followed by epirubicin/cyclophosphamide (EC). Stratification factors were hormone receptor (HR) status (HR versus HR ) and age (<40 versus >= 40 years). The primary endpoint was pathological complete response (pCR; ypTO/is ypNO). A two-sided one-group chi(2)-test was planned to exclude a pCR rate of <= 55% in the PO-EC arm. Secondary end points were other pCR definitions, breast conservation rate, clinical/ imaging response, tolerability and safety. Results: A total of 107 patients were randomised between September 2016 and July 2018; 106 (PO N = 69; PCb N = 37) started treatment. Median age was 47.0 years (range 25.0-71.0); 36.2% had cT1, 61.0% cT2, 2.9% cT3, and 31.8% cN-positive tumours; grade 3 tumours: 86.8%; Ki-67>20%: 89.6%; TNBC: 72.6%; confirmed gBRCA1/2 mutation: 56.2%. The pCR rate with PO was 55.1% [90% confidence interval (CI) 44.5% to 65.3%] versus PCb 48.6% (90% CI 34.3% to 63.2%). Analysis for the stratified subgroups showed higher pCR rates with PO in the cohorts of patients <40 years and HR patients. Conclusion: GeparOLA could not exclude a pCR rate of <= 55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation.

Published
2021

16. Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Author

Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S., Hahnen, E., Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S., and Hahnen, E.

Published
2020

18. Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system

Author

Schmidt, M., primary, Degenhardt, T., additional, Fasching, P.A., additional, Lüftner, D., additional, Müller, V., additional, Thomssen, C., additional, Schem, C., additional, Witzel, I., additional, Decker, T., additional, Tesch, H., additional, Kümmel, S., additional, Uleer, C., additional, Würstlein, R., additional, Hoffmann, O., additional, Warm, M., additional, Marschner, N., additional, Kates, R.E., additional, Schumacher, J., additional, and Harbeck, N., additional

Published
2020
Full Text
View/download PDF

19. 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Author

Hauke, J., primary, Ernst, C., additional, Fasching, P.A., additional, Jackisch, C., additional, Seither, F., additional, Klare, P., additional, Rhiem, K.E., additional, Schmatloch, S., additional, Huober, J., additional, Stefek, A., additional, Seiler, S., additional, Uleer, C., additional, Doering, G., additional, Schneeweiss, A., additional, Denkert, C., additional, Untch, M., additional, Blohmer, J-U., additional, Schmutzler, R.K., additional, Loibl, S., additional, and Hahnen, E., additional

Published
2020
Full Text
View/download PDF

21. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Author

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., Walter-Kirst, R., Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., and Walter-Kirst, R.

Abstract

PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULT Of the 3,198 registered patients, 348 (RS <= 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v60.8%; pNO, 58.2% v59.5%; pT1, 57.6% v52.3%; HR positive, 81.4% v82.2%; RS greater than 25 [in H.R-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), de

Published
2019

22. PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Author

Degenhardt, T., primary, Fasching, P.A., additional, Lüftner, D., additional, Müller, V., additional, Thomssen, C., additional, Schem, C., additional, Witzel, I., additional, Decker, T., additional, Tesch, H., additional, Kuemmel, S., additional, Uleer, C., additional, Wuerstlein, R., additional, Riese, C., additional, Schinköthe, T., additional, Kates, R.E., additional, Schumacher, J., additional, Harbeck, N., additional, and Schmidt, M., additional

Published
2019
Full Text
View/download PDF

23. Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO

Author

Lüftner, D, primary, Schuetz, F, additional, Schneeweiss, A, additional, Grischke, E-M, additional, Bloch, W, additional, Decker, T, additional, Uleer, C, additional, Salat, C, additional, Förster, F, additional, Schmidt, M, additional, Mundhenke, C, additional, Tesch, H, additional, Jackisch, C, additional, Fischer, T, additional, Guderian, G, additional, Hanson, S, additional, and Fasching, P, additional

Published
2019
Full Text
View/download PDF

24. Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Prat, A, additional, Christgen, M, additional, Feuerhake, F, additional, Garke, M, additional, Grischke, E-M, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Kuemmel, S, additional, Pelz, E, additional, Gebauer, D, additional, Paré, L, additional, Kates, R, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2019
Full Text
View/download PDF

25. Abstract P1-15-10: A prospective multicenter real-world study on neoadjuvant treatment and clinical outcome in TNBC patients

Author

Kuehnle, E, primary, Kaur, P, additional, Siggelkow, W, additional, Luebbe, K, additional, Schrader, I, additional, Uleer, C, additional, Noeding, S, additional, Noeding, K-H, additional, Noesselt, T, additional, Arfsten, M, additional, Busch, C, additional, Krentel, N, additional, Hillemanns, P, additional, Dörk, T, additional, and Park-Simon, T-W, additional

Published
2019
Full Text
View/download PDF

26. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Author

Gluz, O., primary, Nitz, U., additional, Liedtke, C., additional, Christgen, M., additional, Grischke, E.-M., additional, Forstbauer, H., additional, Braun, M., additional, Warm, M., additional, Hackmann, J., additional, Uleer, C., additional, Aktas, B., additional, Schumacher, C., additional, Lindner, C., additional, Kümmel, S., additional, Kates, R.E., additional, Potenberg, J., additional, Staib, P., additional, Wuerstlein, R., additional, Kreipe, H.H., additional, and Harbeck, N., additional

Published
2018
Full Text
View/download PDF

28. Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial

Author

Garke, M, additional, Feuerhake, F, additional, Gluz, O, additional, Christgen, M, additional, Kates, R, additional, Grischke, EM, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, C, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Kuemmel, S, additional, Würstlein, R, additional, Nitz, U, additional, Kreipe, H, additional, Harbeck, N, additional, and Liedtke, C, additional

Published
2018
Full Text
View/download PDF

29. Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial

Author

Harbeck, N, primary, Gluz, O, additional, Wuerstlein, R, additional, Clemens, M, additional, Malter, W, additional, Reimer, T, additional, Nuding, B, additional, Stefek, A, additional, Pollmanns, A, additional, Augustin, D, additional, Uleer, C, additional, Lorenz-Salehi, F, additional, Shak, S, additional, Chao, C, additional, Christgen, M, additional, Kates, R, additional, Kreipe, H, additional, and Nitz, U, additional

Published
2018
Full Text
View/download PDF

30. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results

Author

Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H., Harbeck, N., Gluz, O., Nitz, U., Christgen, M., Malter, W., Clemens, M., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Ppllmanns, A., Lorenz-Salehi, F., Uleer, C., Krabisch, P., Kuemmel, S., Liedtke, C., Shak, S., Kates, R., Wurstlein, R., Kreipe, H. H., and Harbeck, N.

Published
2017

31. Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer : WSG-ADAPT TN randomized phase II trial

Author

Potenberg, J, Liedtke, C, Grischke, EM, Warm, M, Staib, P, Harbeck, N, Kreipe, HH, Wuerstlein, R, Kuemmel, S, Lindner, C, Kates, RE, Pelz, E, Uleer, C, Nitz, U, Aktas, B, Forstbauer, H, Schumacher, C, Gluz, O, Braun, M, Kohls, A, Hackmann, J, Clemens, M, Christgen, M, Bangemann, N, and Sotlar, K

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2016

32. Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results

Author

Gluz, O., primary, Nitz, U., additional, Christgen, M., additional, Malter, W., additional, Clemens, M., additional, Reimer, T., additional, Nuding, B., additional, Aktas, B., additional, Stefek, A., additional, Ppllmanns, A., additional, Lorenz-Salehi, F., additional, Uleer, C., additional, Krabisch, P., additional, Kümmel, S., additional, Liedtke, C., additional, Shak, S., additional, Kates, R., additional, Wurstlein, R., additional, Kreipe, H.H., additional, and Harbeck, N., additional

Published
2017
Full Text
View/download PDF

34. Results of the 3rd interim analysis of the non-interventional trial BRAWO - Subanalysis of patients < 70 years and >= 70 years

Author

Tesch, H., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F., Lueftner, D., Tesch, H., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F., and Lueftner, D.

Published
2016

35. Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO

Author

Schuetz, F., Grischke, E-M, Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Jackisch, C., Idiftner, D., Fasching, P. A., Schuetz, F., Grischke, E-M, Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Jackisch, C., Idiftner, D., and Fasching, P. A.

Published
2016

36. Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER plus women - Results of the 3rd interim analysis of BRAWO

Author

Bloch, W., Baumann, F., Zimmer, P., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Tesch, H., Schuetz, F., Lueftner, D., Jackisch, C., Bloch, W., Baumann, F., Zimmer, P., Grischke, E-M, Fasching, P. A., Decker, T., Uleer, C., Schneeweiss, A., Salat, C., Wimberger, P., Mundhenke, C., Foerster, F., Kluth-Pepper, B., Schubert, J., Tesch, H., Schuetz, F., Lueftner, D., and Jackisch, C.

Published
2016

38. Androgenrezeptor (AR) und Forkhead BoxA1 (FOXA1) als Prognosefaktoren beim frühen HER2-negativen Mammakarzinom – eine translationale Substudie im Rahmen der prospektiven Phase-III-WSG-Plan B Studie

Author

Degenhardt, T, primary, Kreipe, HH, additional, Gluz, O, additional, Kates, RE, additional, Liedtke, C, additional, Kraemer, S, additional, Clemens, MR, additional, Nuding, B, additional, Reimer, T, additional, Aktas, B, additional, Kuemmel, S, additional, Just, M, additional, Lorenz-Salehi, F, additional, Uleer, C, additional, Stefek, A, additional, Heyl, V, additional, Würstlein, R, additional, Nitz, U, additional, Christgen, M, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

39. Vergleich der 12-wöchigen neoadjuvanten Chemotherapie mit Nab-Paclitaxel mit Gemcitabine vs. Carboplatin bei Patientinnen mit triple-negativem Mammakarzinom: ADAPT-TN randomiiserte Phase II Studie

Author

Grischke, EM, primary, Gluz, O, additional, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kates, R, additional, Würstlein, R, additional, Kreipe, H, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

40. Treat CTC: Eine innovative Studie zur Elimination von zirkulierenden Tumorzellen beim primären Mammakarzinom

Author

Tzschaschel, M, primary, Trapp, E, additional, Rack, B, additional, Alunni-Fabbroni, M, additional, Messina, C, additional, Müller, V, additional, Fehm, T, additional, Janni, W, additional, Loehberg, C, additional, Wimberger, P, additional, Lorenz, R, additional, Kolberg, HC, additional, Beck, T, additional, Uleer, C, additional, Decker, T, additional, Fett, W, additional, Brudler, O, additional, Sotiriou, C, additional, Pierga, JY, additional, Piccart, M, additional, and Ignatiadis, M, additional

Published
2016
Full Text
View/download PDF

41. Abstract P4-13-06: Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years

Author

Tesch, H, primary, Grischke, E-M, additional, Fasching, PA, additional, Decker, T, additional, Uleer, C, additional, Schneeweiss, A, additional, Salat, C, additional, Wimberger, P, additional, Mundhenke, C, additional, Förster, F, additional, Kluth-Pepper, B, additional, Schubert, J, additional, Bloch, W, additional, Jackisch, C, additional, Schütz, F, additional, and Lüftner, D, additional

Published
2016
Full Text
View/download PDF

42. Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Sotlar, K, additional, Grischke, EM, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kohls, A, additional, Pelz, E, additional, Kates, RE, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

43. Abstract P4-13-08: Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO

Author

Schütz, F, primary, Grischke, E-M, additional, Decker, T, additional, Uleer, C, additional, Schneeweiss, A, additional, Salat, C, additional, Wimberger, P, additional, Mundhenke, C, additional, Förster, F, additional, Kluth-Pepper, B, additional, Schubert, J, additional, Bloch, W, additional, Tesch, H, additional, Jackisch, C, additional, Lüftner, D, additional, and Fasching, PA, additional

Published
2016
Full Text
View/download PDF

44. Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO

Author

Bloch, W, primary, Baumann, F, additional, Zimmer, P, additional, Grischke, E-M, additional, Fasching, PA, additional, Decker, T, additional, Uleer, C, additional, Schneeweiss, A, additional, Salat, C, additional, Wimberger, P, additional, Mundhenke, C, additional, Förster, F, additional, Kluth-Pepper, B, additional, Schubert, J, additional, Tesch, H, additional, Schütz, F, additional, Lüftner, D, additional, and Jackisch, C, additional

Published
2016
Full Text
View/download PDF

45. Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Sotlar, K, additional, Grischke, EM, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kohls, A, additional, Pelz, E, additional, Kates, RE, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

46. Disease characteristics of subgroup patients treated with everolimus plus exemestane for < 12 months, >= 12 to < 18months, and >= 18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO

Author

Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F., Jackisch, C., Lueftner, D., Grischke, E. M., Fasching, P., Decker, T., Schneeweiss, A., Uleer, C., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Tesch, H., Schuetz, F., and Jackisch, C.

Published
2015

47. Results of the 3rd interim analysis of BRAWO - breast cancer treatment with everolimus and exemestane for ER plus women

Author

Tesch, H., Grischke, E-M, Fasching, P., Decker, T., Uleer, C., Schneeweiss, A., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F., Lueftner, D., Tesch, H., Grischke, E-M, Fasching, P., Decker, T., Uleer, C., Schneeweiss, A., Foerster, F., Wimberger, P., Kluth-Pepper, B., Schubert, J., Bloch, W., Jackisch, C., Schuetz, F., and Lueftner, D.

Published
2015

48. LBA13 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Author

Gluz, O., Nitz, U., Liedtke, C., Christgen, M., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Lindner, C., Kümmel, S., Kates, R.E., Potenberg, J., Staib, P., Wuerstlein, R., Kreipe, H.H., and Harbeck, N.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results